Takeda succeeds where other pharmas have failed with PhIII win for cytomegalovirus castoff maribavir
Maribavir, once a trial dud and multiple-time castoff, received new life from the FDA right before Takeda picked up Shire in 2019. Now, Takeda is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
